Cardiac Valve Complications in Prolactinomas Treated With Cabergoline (ValveCab)

This study has been completed.
Sponsor:
Information provided by:
Federico II University
ClinicalTrials.gov Identifier:
NCT00460616
First received: April 13, 2007
Last updated: April 14, 2008
Last verified: October 2007
  Purpose

Dopamine agonists are first-line agents for the treatment of prolactinomas (1) and Parkinson's disease (2). There is evidence supporting a causal relationship between the occurrence of drug-induced "restrictive" valvular heart disease and treatment with pergolide (3): in several cases, the valvulopathy improved when pergolide was discontinued (4). Valvular heart damage has also been reported with the ergot-derived dopamine agonists bromocriptine and cabergoline (5,6).

Two recent studies (7,8) have further demonstrated that both pergolide and cabergoline are associated with an increased risk of new cardiac valve regurgitation in patients treated for Parkinson's disease.

The valvular abnormalities seen with ergot-derived dopamine agonists are similar to those observed in patients receiving ergot alkaloid agents (such as ergotamine and methysergide) in the treatment of migraine, or fenfluramine and dexfenfluramine in the treatment of obesity. These abnormalities also closely resemble carcinoid-related valvulopathies (9).

Cardiac valve disease has never been reported in patients with prolactinomas who require treatment with dopamine-agonists even life-long (1). At variance with patients with Parkinson's disease, patients with prolactinomas are younger and are treated with an average dose of dopamine-agonists that is significantly lower (median bromocriptine dose 5 mg/day and median cabergoline dose 1 mg/week). Because of the young age of treatment beginning (most patients with microprolactinomas start dopamine-agonist treatment in early adulthood), treatment might be continued for over 3 decades: the cumulative risk of low doses of dopamine agonists for such a long period of treatment is currently unknown.

To assess the prevalence of cardiac valve disease in patients treated with cabergoline, we wish to perform an echocardiography screening in a large representative sample of patients with prolactinoma who were treated with cabergoline for at least 12 months and in a group of control subjects recruited prospectively. We wish to evaluate the severity of regurgitation for the mitral, aortic, and tricuspid valves. Changes in cardiac valve apparatus was compared with treatment duration and cumulative cabergoline dose.


Condition Intervention Phase
Prolactinomas
Drug: Cabergoline
Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline

Resource links provided by NLM:


Further study details as provided by Federico II University:

Primary Outcome Measures:
  • Prevalence of regurgitation (graded as mild, moderate, severe) at any cardiac valve. [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]

Enrollment: 50
Study Start Date: January 2007
Study Completion Date: September 2007
Groups/Cohorts Assigned Interventions
1
Patients already receiving treatment with cabergoline.
Drug: Cabergoline
According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
Other Name: Dostinex
2
healthy controls sex and age-matched with the patients

Detailed Description:

Within one week from a clinical observation in the outpatient service, all patients will be admitted to the hospital for a complete endocrine screening, a cardiological visit that will include an electrocardiogram and an echocardiogram.

The endocrine profile will include measurement of IGF-I, PRL, FSH, LH, 17-β-estradiol, testosterone, FT3, FT4, TSH, and cortisol at 8.00 in the morning after an overnight fasting.

The clinical profile will include blood pressure measurement at the right arm, with the subjects in relaxed sitting position. The average of six measurements (three taken by each of two examiners, in the same day of echocardiography, between 8.00-9.00 in the morning) with a mercury sphygmomanometer will be used in all analysis. According with the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (10), hypertension, if present, is classified as mild (Stage 1) when the SBP or DBP were between 140 and 159 mmHg and between 90 and 99 mmHg, respectively; severe (Stage 2) when the SBP or DBP were >160 and >100 mmHg respectively; pre-hypertension is defined as SBP >120¬ and <140 and DBP >80 and <90 mmHg. Heart rate will be also measured.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Three different study populations will be studied.

  • Group 1) Patients already receiving treatment with cabergoline for at least 12 months
  • Group 2) Newly diagnosed patients with hyperprolactinemia who never received treatment with dopamine-agonists
  • Group 3) Non hyperprolactinemic subjects matched with the patients for sex and age to be used as controls.
Criteria

Inclusion Criteria:

  • Patients with documented hyperprolactinemia receiving continuous treatment with cabergoline only for at least 12 months
  • Newly diagnosed patients with prolactinoma never previously receiving dopamine agonists treatment

Exclusion Criteria:

  • A history of cardiac valve abnormalities,
  • Previous use of anorectic drugs or other ergot-derived drugs,
  • Treatment with cabergoline for less than 12 months,
  • Valve calcification, valve regurgitation associated with annular dilatation or excessive leaflet motion,
  • Mitral regurgitation associated with left ventricular wall-motion abnormalities or left ventricular dilatation,
  • Withdrawal from cabergoline treatment for longer than 1 month, according with our treatment protocol (11).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00460616

Locations
Italy
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples
via S. Pansini 5 Naples, Italy, 80131
Sponsors and Collaborators
Federico II University
Investigators
Principal Investigator: Annamaria AL Colao, Prof. Federico II University
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Annamaria Colao, Department of Mol and Clin Endocrinol Oncol
ClinicalTrials.gov Identifier: NCT00460616     History of Changes
Other Study ID Numbers: NeuroendoUnit-2
Study First Received: April 13, 2007
Last Updated: April 14, 2008
Health Authority: Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Italy: The Italian Medicines Agency

Keywords provided by Federico II University:
Prolactin
Prolactinomas
Dopamine-Agonists
Cabergoline
Cardiac valve disease

Additional relevant MeSH terms:
Prolactinoma
Adenoma
Brain Diseases
Central Nervous System Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Hypothalamic Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Nervous System Diseases
Pituitary Diseases
Pituitary Neoplasms
Cabergoline
Anti-Dyskinesia Agents
Antineoplastic Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014